Literature DB >> 16787503

Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance.

Georgios Georgiou1, Vasiliki Karali, Christina Zouvelou, Elias Kyriakou, Maria Dimou, Stamatis Chrisochoou, Paraskevi Greka, Dimitrios Dufexis, Elisavet Vervesou, Evaggelia Dimitriadou, Anna Efthymiou, Loizos Petrikkos, Katerina Dima, Konstantinos Lilakos, Panayiotis Panayiotidis.   

Abstract

The incidence of FLT3 mutations (internal tandem duplication and Asp835) was investigated in bone marrow samples from 97 patients with myelodysplastic syndrome [(MDS); excluding cases with refractory anaemia with excess blasts in transformation] at the time of diagnosis and several time points thereafter. Three patients had FLT3 mutations at presentation. Forty-two patients progressed to acute myeloid leukaemia (AML), including the three patients with FLT3 mutations at MDS diagnosis. Three additional patients acquired FLT3 mutations and progressed to AML in 1 month. FLT3 mutations seem to be a critical additional genetic event that transforms a minority of MDS patients to AML.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16787503     DOI: 10.1111/j.1365-2141.2006.06171.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

Review 1.  Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process.

Authors:  Simon B Zeichner; Martha L Arellano
Journal:  Curr Treat Options Oncol       Date:  2015-08

2.  Prospective nested case-control study of feature genes related to leukemic evolution of myelodysplastic syndrome.

Authors:  Yan Ma; Bobin Chen; Xiaoping Xu; Guowei Lin
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

3.  FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.

Authors:  Naval Daver; Paolo Strati; Elias Jabbour; Tapan Kadia; Raja Luthra; Sa Wang; Keyur Patel; Farhad Ravandi; Jorge Cortes; Xiao Qin Dong; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2012-10-31       Impact factor: 10.047

4.  Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.

Authors:  Talha Badar; Keyur P Patel; Philip A Thompson; Courtney DiNardo; Koichi Takahashi; Monica Cabrero; Gautam Borthakur; Jorge Cortes; Marina Konopleva; Tapan Kadia; Zach Bohannan; Sherry Pierce; Elias J Jabbour; Farhad Ravandi; Naval Daver; Raja Luthra; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Leuk Res       Date:  2015-10-19       Impact factor: 3.156

5.  Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome.

Authors:  Syed A Mian; Alexander E Smith; Austin G Kulasekararaj; Aytug Kizilors; Azim M Mohamedali; Nicholas C Lea; Konstantinos Mitsopoulos; Kevin Ford; Erick Nasser; Thomas Seidl; Ghulam J Mufti
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

Review 6.  Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.

Authors:  Harinder Gill; Anskar Y H Leung; Yok-Lam Kwong
Journal:  Int J Mol Sci       Date:  2016-03-24       Impact factor: 5.923

Review 7.  Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies.

Authors:  Jianbiao Zhou; Wee-Joo Chng
Journal:  World J Clin Oncol       Date:  2018-09-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.